160 related articles for article (PubMed ID: 38611018)
1. Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients.
Mitri F; Machiraju D; Naoum C; Hassel JC
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611018
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
Jessel S; Weiss SA; Austin M; Mahajan A; Etts K; Zhang L; Aizenbud L; Perdigoto AL; Hurwitz M; Sznol M; Herold KC; Kluger HM
Front Oncol; 2022; 12():836859. PubMed ID: 35350573
[TBL] [Abstract][Full Text] [Related]
3. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
5. The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature.
Urai S; Tomofuji S; Bando H; Kanzawa M; Yamamoto M; Fukuoka H; Tsuda M; Iguchi G; Ogawa W
J Neuroendocrinol; 2024 Jun; 36(6):e13395. PubMed ID: 38631695
[TBL] [Abstract][Full Text] [Related]
6. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
7. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
8. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
12. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population.
Wei KZ; Baxter M; Casasola R
Melanoma Manag; 2019 Mar; 6(1):MMT13. PubMed ID: 31236205
[TBL] [Abstract][Full Text] [Related]
13. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
[TBL] [Abstract][Full Text] [Related]
14. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
16. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge.
Park BC; Jung S; Wright JJ; Johnson DB
Oncologist; 2022 Dec; 27(12):e967-e969. PubMed ID: 36288471
[TBL] [Abstract][Full Text] [Related]
18. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.
De Sousa SMC; Sheriff N; Tran CH; Menzies AM; Tsang VHM; Long GV; Tonks KTT
Pituitary; 2018 Jun; 21(3):274-282. PubMed ID: 29380110
[TBL] [Abstract][Full Text] [Related]
19. Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report.
Norwood TG; Wang MJ; Huh WK
Gynecol Oncol Rep; 2019 Nov; 30():100508. PubMed ID: 31737773
[TBL] [Abstract][Full Text] [Related]
20. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.
Kobayashi T; Iwama S; Sugiyama D; Yasuda Y; Okuji T; Ito M; Ito S; Sugiyama M; Onoue T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Nishikawa H; Arima H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
